#China #Shanghai #Juncell Therapeutics #TIL therapy #AACR 2025

Juncell Therapeutics Unveils Cutting-Edge Data on TIL Therapy

In an exciting development on the frontier of cancer treatment, Shanghai Juncell Therapeutics Co., Ltd. will showcase preclinical findings regarding its innovative pretreatment regimen for Tumor-Infiltrating Lymphocyte (TIL) therapy at the upcoming AACR Annual Meeting 2025. This prestigious gathering is set to take place in Chicago from April 25-30, 2025.

Highlighted Findings

A major focus of Juncell's presentation is the significant effect of hydroxychloroquine (HCQ) in enhancing the anti-tumor efficacy of TIL therapy. The research indicates that HCQ may elevate the levels of membrane MHC-I proteins on tumor cells, thereby improving the cancer cell targeting capabilities of TILs. This is an important development, as it suggests that HCQ could act as a powerful adjunct to TIL therapy, enhancing its effectiveness without detrimental effects on the proliferation of TILs themselves.

Moreover, the study provides insight into HCQ’s effect on surface PD-L1 expression, revealing that its influence was not as pronounced as that of interferon-gamma (IFN-γ). This differentiation is crucial for clinicians and researchers working to optimize treatment protocols based on these findings.

Presentation Details

Juncell Therapeutics is set to present these findings in a poster session. The details are as follows:

• - Abstract Number: 5827
• - Abstract Title: Hydroxychloroquine increases the tumor killing efficiency via elevating the membrane MHC-I protein levels of tumor cells
• - Session Title: Immunomodulatory Agents and Interventions
• - Location: Poster Section 29
• - Poster Board Number: 3
• - Presentation Time: 2:00 PM - 5:00 PM CST, April 29, 2025

About Juncell Therapeutics

Juncell Therapeutics is at the forefront of biotechnology, dedicated to making TIL therapy more effective and accessible for solid tumor treatments. Their proprietary DeepTIL® and NovaGMP® platforms focus on overcoming traditional barriers associated with TIL therapies, ensuring these treatments are robust and cost-effective.

The company's commitment to innovation is reflected in its clinical-stage TIL therapies, which have shown promising results for various advanced solid tumors, including lung, pancreatic, ovarian, and triple-negative breast cancers, among others. With several patients demonstrating complete responses and long-term tumor-free survivals, Juncell Therapeutics is making strides towards more effective cancer therapies.

For more detailed information, stakeholders and interested parties can visit their website or follow them on LinkedIn.

Conclusion

As the AACR Annual Meeting approaches, the unveiling of this preclinical data positions Juncell Therapeutics as a significant player in the ongoing battle against cancer. Their innovative approach leveraging hydroxychloroquine in TIL therapy could set the groundwork for future clinical trials, with the potential to revolutionize standards in cancer treatment.